Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 5/20 | 0.52 |
| ▸ | RORC | P51449 | 4/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 6/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993866 | 0.90 | CNR2 (0.46) | SCN2ARORCNPY5RCNR2CYP11B1 | |
| SCHEMBL4055412 | 0.85 | RORC (0.57) | RORCCNR2CYP11B1NR1I2NR1H2 | |
| SCHEMBL1997923 | 0.80 | RORC (0.50) | RORCCNR2CYP11B1NR1I2NR1H2 | |
| SCHEMBL2003917 | 0.80 | SCN2A (0.50) | SCN2ARORCNPY5RCNR2CYP11B1 | |
| SCHEMBL1998946 | 0.74 | PTPN2 (0.52) | RORCCYP11B1NR1I2NR1H2NR1H3 | |
| SCHEMBL2001054 | 0.73 | CNR1 (0.57) | RORCCNR2CYP11B1NR1I2NR1H2 | |
| SCHEMBL2001224 | 0.73 | NPC1 (0.48) | RORCCYP11B1NR1I2NR1H2NR1H3 | |
| SCHEMBL2001965 | 0.73 | CA2 (0.46) | RORCNR1I2NR1H2NR1H3 | |
| SCHEMBL4062546 | 0.73 | RORC (0.53) | RORCCNR2CYP11B1NR1I2NR1H2 | |
| SCHEMBL1999370 | 0.72 | CNR1 (0.57) | RORCCNR2NR1I2NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2009035997-A2 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009035997-A2 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CNR1, CNR2, TRPV1 | SCN2A 1778/4885RORC 21/4885NPY5R 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.